Evidence map›Paper›PMID 35580962›Full record

ArticleGut2023

Hepatic p63 regulates glucose metabolism by repressing SIRT1.

Maria J Gonzalez-Rellan, Eva Novoa, Natalia da Silva Lima, Amaia Rodriguez, Christelle Veyrat-Durebex, Samuel Seoane, Begoña Porteiro, Marcos F Fondevila, Uxia Fernandez, Marta Varela-Rey and 13 more

Open access · hybridAbstract read
In one paragraph

Article in Gut, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Nicotinamide Metabolism Constrains Memory CD8Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 6 institutions in 5 countries.

Maria J Gonzalez-Rellan *Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.ORCID 0000-0001-8986-9244
Eva Novoa *Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Natalia da Silva LimaDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Amaia RodriguezCIBERobn, CIBER Fisiopatologia de la Obesidad y Nutricion, Spain, Spain.
Christelle Veyrat-DurebexDepartment of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Samuel SeoaneDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Begoña PorteiroDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Marcos F FondevilaDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.ORCID 0000-0002-5099-3421
Uxia FernandezDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Marta Varela-ReyGene Regulatory Control in Disease, CIMUS University of Santiago de Compostela, Santiago de Compostela, Spain.
Ana SenraDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Cristina IglesiasDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Adriana EscuderoDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Miguel FidalgoDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Diana GuallarDepartment of Biochemistry, CIMUS, Instituto de Investigación Sanitaria, Santiago de Compostela, Spain.
Roman Perez-FernandezDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Vincent PrevotLaboratory of Development and Plasticity of the Neuroendocrine Brain, University of Lille, INSERM, European Genomic Institute for Diabetes (EGID), Paris, France.
Markus SchwaningerUniversity of Lübeck, Institute for Experimental and Clinical Pharmacology and Toxicology, Lübeck, Germany.
Miguel LópezDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Carlos DieguezDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.
Roberto CoppariDepartment of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Gema FrühbeckCIBERobn, CIBER Fisiopatologia de la Obesidad y Nutricion, Spain, Spain.
Ruben NogueirasDepartment of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain ruben.nogueiras@usc.es.ORCID 0000-0002-9976-9930
Universidade de Santiago de Compostela · ESSpanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition · ESUniversity of Geneva · CHInserm · FRInstituto de Investigación Sanitaria de Santiago · ESUniversity of Lübeck · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivep63 is a transcription factor within the p53 protein family that has key roles in development, differentiation and prevention of senescence, but its metabolic actions remain largely unknown. Herein, we investigated the physiological role of p63 in glucose metabolism.

designWe used cell lines and mouse models to genetically manipulate p63 in hepatocytes. We also measured p63 in the liver of patients with obesity with or without type 2 diabetes (T2D).

resultsWe show that hepatic p63 expression is reduced on fasting. Mice lacking the specific isoform TAp63 in the liver (p63LKO) display higher postprandial and pyruvate-induced glucose excursions. These mice have elevated SIRT1 levels, while SIRT1 knockdown in p63LKO mice normalises glycaemia. Overexpression of TAp63 in wild-type mice reduces postprandial, pyruvate-induced blood glucose and SIRT1 levels. Studies carried out in hepatocyte cell lines show that TAp63 regulates SIRT1 promoter by repressing its transcriptional activation. TAp63 also mediates the inhibitory effect of insulin on hepatic glucose production, as silencing TAp63 impairs insulin sensitivity. Finally, protein levels of TAp63 are reduced in obese persons with T2D and are negatively correlated with fasting glucose and homeostasis model assessment index.

conclusionsThese results demonstrate that p63 physiologically regulates glucose homeostasis.

Indexed as

Diabetes Mellitus, Type 2Sirtuin 1Trans-ActivatorsAnimalsGlucoseLiverMicePyruvatesGlucosePyruvatesSirt1 protein, mouseSirtuin 1Trans-ActivatorsTrp63 protein, mousediabetes mellitusdietglucose metabolismliver

Identifiers

PMID35580962
PMCPMC9933162
OpenAlexW4280644951

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.